Puma Biotechnology (PBYI) Stock Price, News & Analysis

Company Overview

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing medicines for cancer treatment. Its work centers on targeted therapies, particularly treatments for breast cancer.

The company’s principal product is Nerlynx (neratinib), an oral HER2-targeted medicine. In the United States, it is approved for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based treatment, and for some patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine.

Puma was founded in 2010 and licensed neratinib from Pfizer. It markets Nerlynx in the United States and relies on commercial partners for distribution in certain international markets. The company is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $7.81 to $8.12
• 50-Day Range: $8.08 to $11.26
• 52-Week Range: $4.76 to $11.50
• Volume: 56,107 shs
• Average Volume: 351,213 shs
• Market Capitalization: $412.05 million
• P/E Ratio: 17.33
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Puma Biotechnology Stock Analysis - MarketRank™

Puma Biotechnology scored higher than 25% of companies evaluated by MarketBeat, and ranked 796th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Puma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Downside Risk

Puma Biotechnology has a consensus price target of $6.00, representing about 24.9% downside from its current price of $7.99.

Amount of Analyst Coverage

Puma Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -62.16%

Earnings Growth

Earnings for Puma Biotechnology are expected to decrease by -62.16% in the coming year, from $0.37 to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Puma Biotechnology is 17.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Puma Biotechnology is 17.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.41.

Price to Book Value per Share Ratio

Puma Biotechnology has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.70% of the float of Puma Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Puma Biotechnology has a short interest ratio ("days to cover") of 11.51, which indicates bearish sentiment.

Change versus previous month

Short interest in Puma Biotechnology has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Puma Biotechnology does not currently pay a dividend.

Dividend Growth

Puma Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.65

News Sentiment

Puma Biotechnology has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for PBYI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $612,308.00 in company stock.

Percentage Held by Insiders

22.20% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PBYI
• CIK: 1401667
• Web: www.pumabiotechnology.com
• Phone: (424) 248-6500
• Fax: 424-248-6501
• Employees: 179
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Puma Biotechnology: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: -24.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.46
• Trailing P/E Ratio: 17.33
• Forward P/E Ratio: 56.93
• P/E Growth: N/A
• Net Income: $31.11 million
• Net Margins: 10.26%
• Pretax Margin: 12.12%
• Return on Equity: 17.50%
• Return on Assets: 11.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.03
• Quick Ratio: 2.64

Sales & Book Value

• Annual Sales: $228.40 million
• Price / Sales: 1.80
• Cash Flow: $0.82 per share
• Price / Cash Flow: 9.69
• Book Value: $2.84 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 51,700,000
• Free Float: 40,221,000
• Market Cap: $412.05 million
• Optionable: Optionable
• Beta: 1.40